Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Terminated 3Unknown 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 8Gastrointestinal 8Other hematologic neoplasm 5Myeloid 3Lymphoid 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1Dermatologic 1Classical hematology 1Breast 1

Conditions

Melanoma 1

Interventions

pembrolizumab 65Nivolumab 58Ipilimumab 32Cyclophosphamide 22Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13cemiplimab 13fludarabine 12Opdualag 12binimetinib 10Blood Specimen Collection 10aldesleukin 9Radiosurgery 9encorafenib 8Interleukin-2 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Radiotherapy 5Disulfides 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Imatinib Mesylate × Dermatologic × Clear all
NCT04598009 2026-06-04

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

University of California, San Francisco

Phase 2 Recruiting
25 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡